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Phosphatidylinositol may be phosphorylated at either 3- or 4- positions on the inositol ring by PI 3-kinases or PI
4-kinases, respectively.
Phosphatidylinositol 3-kinases
Phosphatidylinositol 3-kinases (PI3K, provisional nomenclature) catalyse the introduction of a phosphate into the
3-position of phosphatidylinositol (PI), phosphatidylinositol 4-phosphate (PIP) or phosphatidylinositol 4,5-
bisphosphate (PIP2). There is evidence that PI3K can also phosphorylate serine/threonine residues on proteins.
In addition to the classes described below, further serine/threonine protein kinases, including ATM (Q13315) and
mTOR (P42345), have been described to phosphorylate phosphatidylinositol and have been termed PI3K-
related kinases. Structurally, PI3Ks have common motifs of at least one C2, calcium-binding domain and helical
domains, alongside structurally-conserved catalytic domains. wortmannin and LY 294002 are widely-used
inhibitors of PI3K activities. wortmannin is irreversible and shows modest selectivity between Class I and Class II
PI3K, while LY294002 is reversible and selective for Class I compared to Class II PI3K.
Class I PI3Ks (EC 2.7.1.153) phosphorylate phosphatidylinositol 4,5-bisphosphate to generate
phosphatidylinositol 3,4,5-trisphosphate and are heterodimeric, matching catalytic and regulatory subunits.
Class IA PI3Ks include p110α, p110β and p110δ catalytic subunits, with predominantly p85 and p55 regulatory
subunits. The single catalytic subunit that forms Class IB PI3K is p110γ. Class IA PI3Ks are more associated
with receptor tyrosine kinase pathways, while the Class IB PI3K is linked more with GPCR signalling.
Class II PI3Ks (EC 2.7.1.154) phosphorylate phosphatidylinositol to generate phosphatidylinositol 3-phosphate
(and possibly phosphatidylinositol 4-phosphate to generate phosphatidylinositol 3,4-bisphosphate). Three
monomeric members exist, PI3K-C2α, β and β, and include Ras-binding, Phox homology and two C2domains.
The only class III PI3K isoform (EC 2.7.1.137) is a heterodimer formed of a catalytic subunit (VPS34) and
regulatory subunit (VPS15).
Phosphatidylinositol 4-kinases
Phosphatidylinositol 4-kinases (EC 2.7.1.67) generate phosphatidylinositol 4-phosphate and may be divided into
higher molecular weight type III and lower molecular weight type II forms.
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    Enzymes
            PI4KIIIα/PIK4CA(phosphatidylinositol 4-kinase alpha)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2148
            PI3Kα(phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2153
            PI4KIIIβ/PIK4CB(phosphatidylinositol 4-kinase beta)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2149
            PI3Kβ(phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2154
            PI4KIIα/PI4K2A(phosphatidylinositol 4-kinase type 2 alpha)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2498
            PI3Kγ(phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156
            PI4KIIβ/PI4K2B(phosphatidylinositol 4-kinase type 2 beta)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2499
            PI3Kδ(phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155
            p85α/PIK3R1(phosphoinositide-3-kinase regulatory subunit 1)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2503
            p85β/PIK3R2(phosphoinositide-3-kinase regulatory subunit 2)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2504
            p55γ/PIK3R3(phosphoinositide-3-kinase regulatory subunit 3)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2505
            p150/VPS15/PIK3R4(phosphoinositide-3-kinase regulatory subunit 4)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2157
            p101/PIK3R5(phosphoinositide-3-kinase regulatory subunit 5)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2506
            p87/PIK3R6(phosphoinositide-3-kinase regulatory subunit 6)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2507
            C2α/PIK3C2A(phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2150
            C2β/PIK3C2B(phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2151
            C2γ/PIK3C2G(phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2288
            VPS34(phosphatidylinositol 3-kinase catalytic subunit type 3)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2152
References
1. Adams JL, Smothers J, Srinivasan R and Hoos A. (2015) Big opportunities for small molecules in immuno-
oncology. Nat Rev Drug Discov 14: 603-22 [PMID:26228631]
2. Ali AY, Wu X, Eissa N, Hou S, Ghia JE, Murooka TT, Banerji V, Johnston JB, Lin F and Gibson SB et al..
(2018) Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration. Leukemia 32:
1958-1969 [PMID:29479062]
3. Ali K, Soond DR, Piñeiro R, Hagemann T, Pearce W, Lim EL, Bouabe H, Scudamore CL, Hancox T and
Maecker H et al.. (2014) Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance
to cancer. Nature 510: 407-11 [PMID:24919154]
4. Allen RA, Brookings DC, Powell MJ, Delgado J, Shuttleworth LK, Merriman M, Fahy IJ, Tewari R, Silva JP
and Healy LJ et al.. (2017) Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of
PI3Kδ. J. Pharmacol. Exp. Ther. 361: 429-440 [PMID:28442583]
5. Angulo I, Vadas O, Garçon F, Banham-Hall E, Plagnol V, Leahy TR, Baxendale H, Coulter T, Curtis J and
Wu C et al.. (2013) Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and
airway damage. Science 342: 866-71 [PMID:24136356]
6. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM
2
and Knight ZA. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and
phosphoinositide kinases. Nat. Chem. Biol. 4: 691-9 [PMID:18849971]
7. Backer JM. (2008) The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem. J. 410:
1-17 [PMID:18215151]
8. Balla A, Kim YJ, Varnai P, Szentpetery Z, Knight Z, Shokat KM and Balla T. (2008) Maintenance of
hormone-sensitive phosphoinositide pools in the plasma membrane requires phosphatidylinositol 4-kinase
IIIalpha. Mol. Biol. Cell 19: 711-21 [PMID:18077555]
9. Balla A, Tuymetova G, Barshishat M, Geiszt M and Balla T. (2002) Characterization of type II
phosphatidylinositol 4-kinase isoforms reveals association of the enzymes with endosomal vesicular
compartments. J. Biol. Chem. 277: 20041-50 [PMID:11923287]
10. Barda DA and Mader MM.. (2013) PI3 kinase/mTOR dual inhibitor. Patent number: US8440829 B2.
11. Barlaam B, Cosulich S, Delouvrié B, Ellston R, Fitzek M, Germain H, Green S, Hancox U, Harris CS and
Hudson K et al.. (2015) Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-
ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of
PI3Kα and PI3Kδ for the treatment of cancers. Bioorg. Med. Chem. Lett. 25: 5155-62 [PMID:26475521]
12. Bergamini G, Bell K, Shimamura S, Werner T, Cansfield A, Müller K, Perrin J, Rau C, Ellard K and Hopf C
et al.. (2012) A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. Nat. Chem. Biol.
8: 576-82 [PMID:22544264]
13. Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Liu Y and Rommel C
et al.. (2010) The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.
Nat. Chem. Biol. 6: 117-24 [PMID:20081827]
14. Bonazzi S, Goold CP, Gray A, Thomsen NM, Nunez J, Karki RG, Gorde A, Biag JD, Malik HA and Sun Y
et al.. (2020) Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of
Rapamycin (mTOR) for CNS Disorders. J. Med. Chem. 63: 1068-1083 [PMID:31955578]
15. Borsari C, Rageot D, Dall'Asen A, Bohnacker T, Melone A, Sele AM, Jackson E, Langlois JB, Beaufils F
and Hebeisen P et al.. (2019) A Conformational Restriction Strategy for the Identification of a Highly
Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. J. Med. Chem. 62: 8609-8630 [PMID:31465220]
16. Braun M-G, Hanan E, Staben ST, Heald RA, Macleod C and Elliott R. (2017) Benzoxazepin oxazolidinone
compounds and methods of use Patent number: US20170015678.
17. Brown SD and Matthews DJ. (2012) (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl
and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds
for use in treating proliferative diseases Patent number: WO2012135160A1.
18. Burger MT, Pecchi S, Wagman A, Ni ZJ, Knapp M, Hendrickson T, Atallah G, Pfister K, Zhang Y and
Bartulis S et al.. (2011) Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I
PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett 2: 774-9 [PMID:24900266]
19. Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C and
Françon B et al.. (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse
models of rheumatoid arthritis. Nat. Med. 11: 936-43 [PMID:16127437]
20. Canaud G. (2017) BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED
OVERGROWTH SPECTRUM (PROS - CLOVES SYNDROME) Patent number: WO2017140828.
21. Cano C, Saravanan K, Bailey C, Bardos J, Curtin NJ, Frigerio M, Golding BT, Hardcastle IR, Hummersone
MG and Menear KA et al.. (2013) 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-
ones endowed with dual DNA-PK/PI3-K inhibitory activity. J. Med. Chem. 56: 6386-401 [PMID:23855836]
22. Castro-Falcón G, Seiler GS, Demir Ö, Rathinaswamy MK, Hamelin D, Hoffmann RM, Makowski SL, Letzel
AC, Field SJ and Burke JE et al.. (2018) Neolymphostin A Is a Covalent Phosphoinositide 3-Kinase
(PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitor That Employs an Unusual Electrophilic
Vinylogous Ester. J. Med. Chem. 61: 10463-10472 [PMID:30380865]
23. Certal V, Carry JC, Halley F, Virone-Oddos A, Thompson F, Filoche-Rommé B, El-Ahmad Y, Karlsson A,
Charrier V and Delorme C et al.. (2014) Discovery and optimization of pyrimidone indoline amide PI3Kβ
inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers. J. Med.
Chem. 57: 903-20 [PMID:24387221]
24. Certal V, Halley F, Virone-Oddos A, Delorme C, Karlsson A, Rak A, Thompson F, Filoche-Rommé B, El-
Ahmad Y and Carry JC et al.. (2012) Discovery and optimization of new benzimidazole- and benzoxazole-
pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-
deficient cancers. J. Med. Chem. 55: 4788-805 [PMID:22524426]
25. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO and Johnson TW et
al.. (2013) Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-
Based Drug Design. ACS Med Chem Lett 4: 91-7 [PMID:24900568]
26. Cherian PT, Koikov LN, Wortman MD and Knittel JJ. (2009) Exploring the PI3K alpha and gamma binding
sites with 2,6-disubstituted isonicotinic derivatives. Bioorg. Med. Chem. Lett. 19: 2215-9 [PMID:19297156]
27. Collier PN, Martinez-Botella G, Cornebise M, Cottrell KM, Doran JD, Griffith JP, Mahajan S, Maltais F,
Moody CS and Huck EP et al.. (2015) Structural basis for isoform selectivity in a class of benzothiazole
inhibitors of phosphoinositide 3-kinase γ. J. Med. Chem. 58: 517-21 [PMID:24754609]
28. Cooke NG, Fernandes GDSP, Graveleau N, Hebach C, Hogenauer K, Hollingworth G, Smith AB,
3
Soldermann N, Stowasser F and Strang R et al.. (2012) Tetrahydro-pyrido-pyrimidine derivatives Patent
number: WO2012004299.
29. Crank MC, Grossman JK, Moir S, Pittaluga S, Buckner CM, Kardava L, Agharahimi A, Meuwissen H,
Stoddard J and Niemela J et al.. (2014) Mutations in PIK3CD can cause hyper IgM syndrome (HIGM)
associated with increased cancer susceptibility. J. Clin. Immunol. 34: 272-6 [PMID:24610295]
30. Cushing TD, Hao X, Shin Y, Andrews K, Brown M, Cardozo M, Chen Y, Duquette J, Fisher B and
Gonzalez-Lopez de Turiso F et al.. (2015) Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-
2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and
autoimmune disease. J. Med. Chem. 58: 480-511 [PMID:25469863]
31. D'Angelo ND, Kim TS, Andrews K, Booker SK, Caenepeel S, Chen K, D'Amico D, Freeman D, Jiang J and
Liu L et al.. (2011) Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase
(PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors. J. Med. Chem. 54: 1789-811
[PMID:21332118]
32. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK and Zarrinkar PP.
(2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29: 1046-51
[PMID:22037378]
33. de la Morena M, Haire RN, Ohta Y, Nelson RP, Litman RT, Day NK, Good RA and Litman GW. (1995)
Predominance of sterile immunoglobulin transcripts in a female phenotypically resembling Bruton's
agammaglobulinemia. Eur. J. Immunol. 25: 809-15 [PMID:7705412]
34. Deau MC, Heurtier L, Frange P, Suarez F, Bole-Feysot C, Nitschke P, Cavazzana M, Picard C, Durandy A
and Fischer A et al.. (2014) A human immunodeficiency caused by mutations in the PIK3R1 gene. J. Clin.
Invest. 124: 3923-8 [PMID:25133428]
35. Dittmann A, Werner T, Chung CW, Savitski MM, Fälth Savitski M, Grandi P, Hopf C, Lindon M, Neubauer
G and Prinjha RK et al.. (2014) The commonly used PI3-kinase probe LY294002 is an inhibitor of BET
bromodomains. ACS Chem. Biol. 9: 495-502 [PMID:24533473]
36. Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, Menon S, Wang Z, Honda A and Pardee
G et al.. (2014) Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin
degradation and iron homeostasis in vivo. Nat. Cell Biol. 16: 1069-79 [PMID:25327288]
37. Down K, Amour A, Baldwin IR, Cooper AW, Deakin AM, Felton LM, Guntrip SB, Hardy C, Harrison ZA and
Jones KL et al.. (2015) Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of
Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease. J. Med. Chem. 58: 7381-99
[PMID:26301626]
38. Dulau Florea AE, Braylan RC, Schafernak KT, Williams KW, Daub J, Goyal RK, Puck JM, Rao VK,
Pittaluga S and Holland SM et al.. (2017) Abnormal B-cell maturation in the bone marrow of patients with
germline mutations in PIK3CD. J. Allergy Clin. Immunol. 139: 1032-1035.e6 [PMID:27697496]
39. Evans CA, Liu T, Lescarbeau A, Nair SJ, Grenier L, Pradeilles JA, Glenadel Q, Tibbitts T, Rowley AM and
DiNitto JP et al.. (2016) Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as
an Immuno-Oncology Clinical Candidate. ACS Med Chem Lett 7: 862-7 [PMID:27660692]
40. Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina
MM and Gillies McKenna W et al.. (2012) Targeting ATR in vivo using the novel inhibitor VE-822 results in
selective sensitization of pancreatic tumors to radiation. Cell Death Dis 3: e441 [PMID:23222511]
41. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P and
Eccles SA et al.. (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-
ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable
inhibitor of class I PI3 kinase for the treatment of cancer . J. Med. Chem. 51: 5522-32 [PMID:18754654]
42. Fraser C, Carragher NO and Unciti-Broceta A. (2016) eCF309: a potent, selective and cell-permeable
mTOR inhibitor Medchemcomm 7: 471-477
43. Furet P, Guagnano V, Fairhurst RA, Imbach-Weese P, Bruce I, Knapp M, Fritsch C, Blasco F, Blanz J and
Aichholz R et al.. (2013) Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase
alpha inhibitor selected for clinical evaluation. Bioorg. Med. Chem. Lett. 23: 3741-8 [PMID:23726034]
44. Gangadhara G, Dahl G, Bohnacker T, Rae R, Gunnarsson J, Blaho S, Öster L, Lindmark H, Karabelas K
and Pemberton N et al.. (2019) A class of highly selective inhibitors bind to an active state of PI3Kγ. Nat.
Chem. Biol. 15: 348-357 [PMID:30718815]
45. Gehrmann T, Gülkan H, Suer S, Herberg FW, Balla A, Vereb G, Mayr GW and Heilmeyer Jr LM. (1999)
Functional expression and characterisation of a new human phosphatidylinositol 4-kinase PI4K230.
Biochim. Biophys. Acta 1437: 341-56 [PMID:10101268]
46. Goldberg FW, Finlay MRV, Ting AKT, Beattie D, Lamont GM, Fallan C, Wrigley GL, Schimpl M, Howard
MR and Williamson B et al.. (2020) The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-
yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective
DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. J. Med. Chem. [PMID:31851518]
47. Gopalsamy A, Bennett EM, Shi M, Zhang WG, Bard J and Yu K. (2012) Identification of pyrimidine
derivatives as hSMG-1 inhibitors. Bioorg. Med. Chem. Lett. 22: 6636-41 [PMID:23021994]
48. Griffin RJ, Fontana G, Golding BT, Guiard S, Hardcastle IR, Leahy JJ, Martin N, Richardson C, Rigoreau L
and Stockley M et al.. (2005) Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of
4
DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human
tumor cell line in vitro. J. Med. Chem. 48: 569-85 [PMID:15658870]
49. Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B and
Fitzek M et al.. (2015) Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast
and prostate tumors alone and in combination with docetaxel. Mol. Cancer Ther. 14: 48-58
[PMID:25398829]
50. Harris SJ, Foster JG and Ward SG. (2009) PI3K isoforms as drug targets in inflammatory diseases:
lessons from pharmacological and genetic strategies. Curr Opin Investig Drugs 10: 1151-62
[PMID:19876783]
51. Hart S, Novotny-Diermayr V, Goh KC, Williams M, Tan YC, Ong LC, Cheong A, Ng BK, Amalini C and
Madan B et al.. (2013) VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment
of cancer. Mol. Cancer Ther. 12: 151-61 [PMID:23270925]
52. Hausser A, Storz P, Märtens S, Link G, Toker A and Pfizenmaier K. (2005) Protein kinase D regulates
vesicular transport by phosphorylating and activating phosphatidylinositol-4 kinase IIIbeta at the Golgi
complex. Nat. Cell Biol. 7: 880-6 [PMID:16100512]
53. Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S
and Raynaud FI et al.. (2007) Synthesis and biological evaluation of sulfonylhydrazone-substituted
imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. 15: 5837-44
[PMID:17601739]
54. Heffron TP, Ndubaku CO, Salphati L, Alicke B, Cheong J, Drobnick J, Edgar K, Gould SE, Lee LB and
Lesnick JD et al.. (2016) Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant
Inhibitor of PI3K and mTOR. ACS Med Chem Lett 7: 351-6 [PMID:27096040]
55. Henley ZA, Amour A, Barton N, Bantscheff M, Bergamini G, Bertrand SM, Convery M, Down K,
Dümpelfeld B and Edwards CD et al.. (2020) Optimization of Orally Bioavailable PI3Kδ Inhibitors and
Identification of Vps34 as a Key Selectivity Target. J. Med. Chem. 63: 638-655 [PMID:31855425]
56. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C and
Bonham MJ et al.. (2012) The translational landscape of mTOR signalling steers cancer initiation and
metastasis. Nature 485: 55-61 [PMID:22367541]
57. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE,
Dopheide SM and Yuan Y et al.. (2005) PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat.
Med. 11: 507-14 [PMID:15834429]
58. Jalota-Badhwar A, Bhatia DR, Boreddy S, Joshi A, Venkatraman M, Desai N, Chaudhari S, Bose J, Kolla
LS and Deore V et al.. (2015) P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin
Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity. Mol. Cancer Ther. 14:
1095-106 [PMID:25700704]
59. Jović M, Kean MJ, Szentpetery Z, Polevoy G, Gingras AC, Brill JA and Balla T. (2012) Two
phosphatidylinositol 4-kinases control lysosomal delivery of the Gaucher disease enzyme, β-
glucocerebrosidase. Mol. Biol. Cell 23: 1533-45 [PMID:22337770]
60. Kim O, Jeong Y, Lee H, Hong SS and Hong S. (2011) Design and synthesis of imidazopyridine analogues
as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis. J. Med. Chem. 54: 2455-66
[PMID:21388141]
61. King-Underwood J, Ito K, Murray PJ, Brookfield FA and Brown CJ. (2012) QUINAZOLIN-4 (3H) -ONE
DERIVATIVES USED AS PI3 KINASE INHIBITORS Patent number: WO2012052753.
62. Knight SD, Adams ND, Burgess JL, Chaudhari AM, Darcy MG, Donatelli CA, Luengo JI, Newlander KA,
Parrish CA and Ridgers LH et al.. (2010) Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and
the Mammalian Target of Rapamycin. ACS Med Chem Lett 1: 39-43 [PMID:24900173]
63. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla
A and Toth B et al.. (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in
insulin signaling. Cell 125: 733-47 [PMID:16647110]
64. Knight ZA and Shokat KM. (2005) Features of selective kinase inhibitors. Chem. Biol. 12: 621-37
[PMID:15975507]
65. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux
MM and Deininger M et al.. (2011) CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor
for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117: 591-4
[PMID:20959606]
66. Li Y-L, Metcalf BW and Combs AP. (2011) Pyrimidinones as PI3K inhibitors Patent number:
WO2011008487.
67. Li Y-L, Yao W, Combs AP, Yue EW, Mei S, Zhu W, Glenn J, Maduskuie TP Jr, Sparks RB and Douty B.
(2013) Heterocyclylamines as pi3k inhibitors Patent number: WO2013033569A1.
68. Lin S, Jin J, Liu Y, Tian H, Zhang Y, Fu R, Zhang J, Wang M, Du T and Ji M et al.. (2019) Discovery of 4-
Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. J.
Med. Chem. 62: 8873-8879 [PMID:31335136]
69. Liu F, Wang J, Yang X, Li B, Wu H, Qi S, Chen C, Liu X, Yu K and Wang W et al.. (2016) Discovery of a
Highly Selective STK16 Kinase Inhibitor. ACS Chem. Biol. 11: 1537-43 [PMID:27082499]
5
70. Liu KK, Zhu J, Smith GL, Yin MJ, Bailey S, Chen JH, Hu Q, Huang Q, Li C and Li QJ et al.. (2011) Highly
Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity. ACS Med Chem Lett 2:
809-13 [PMID:24900269]
71. Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, Fracasso PR, Wilkie DP, Hentemann
M and Wilhelm SM et al.. (2013) BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent
p110α and p110δ activities in tumor cell lines and xenograft models. Mol. Cancer Ther. 12: 2319-30
[PMID:24170767]
72. Liu Q, Shi Q, Marcoux D, Batt DG, Cornelius L, Qin LY, Ruan Z, Neels J, Beaudoin-Bertrand M and
Srivastava AS et al.. (2017) Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-
Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders. J. Med. Chem. 60: 5193-5208
[PMID:28541707]
73. Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM and Gray NS. (2011) Discovery of
9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a
potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of
cancer. J. Med. Chem. 54: 1473-80 [PMID:21322566]
74. Liu Y, Shreder KR, Gai W, Corral S, Ferris DK and Rosenblum JS. (2005) Wortmannin, a widely used
phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol. 12: 99-
107 [PMID:15664519]
75. Lucas CL, Chandra A, Nejentsev S, Condliffe AM and Okkenhaug K. (2016) PI3Kδ and primary
immunodeficiencies. Nat. Rev. Immunol. 16: 702-714 [PMID:27616589]
76. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, Avery DT, Moens L, Cannons JL and
Biancalana M et al.. (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K
catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat. Immunol. 15: 88-97
[PMID:24165795]
77. Luo Y, Xia Y, Wang W, Li Z, Jin Y, Gong Y, He T, Li Q, Li C and Yang J. (2018) Identification of a novel
de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ
syndrome. Clin. Immunol. 197: 60-67 [PMID:30138677]
78. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A and
Schoemaker K et al.. (2008) Identification and characterization of NVP-BEZ235, a new orally available
dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor
activity. Mol. Cancer Ther. 7: 1851-63 [PMID:18606717]
79. Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S and
Birle D et al.. (2012) Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral
phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann.
Oncol. 23: 2399-408 [PMID:22357447]
80. Methot JL, Zhou H, Kattar SD, McGowan MA, Wilson K, Garcia Y, Deng Y, Altman M, Fradera X and
Lesburg C et al.. (2019) Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved
Tolerability. J. Med. Chem. 62: 4370-4382 [PMID:30986068]
81. Meyers R and Cantley LC. (1997) Cloning and characterization of a wortmannin-sensitive human
phosphatidylinositol 4-kinase. J. Biol. Chem. 272: 4384-90 [PMID:9020160]
82. Mårdh CK, Root J, Uddin M, Stenvall K, Malmgren A, Karabelas K and Thomas M. (2017) Targets of
Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease. J
Immunol Res 2017: 5273201 [PMID:28596972]
83. Nacht M, Qiao L, Sheets MP, St Martin T, Labenski M, Mazdiyasni H, Karp R, Zhu Z, Chaturvedi P and
Bhavsar D et al.. (2013) Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the
Lipid Kinase PI3Kα. J. Med. Chem. 56: 712-21 [PMID:23360348]
84. Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, Bull R, Do S, Dotson J and
Dudley D et al.. (2013) Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-
dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-
sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor
activity. J. Med. Chem. 56: 4597-610 [PMID:23662903]
85. Nylander S, Kull B, Björkman JA, Ulvinge JC, Oakes N, Emanuelsson BM, Andersson M, Skärby T,
Inghardt T and Fjellström O et al.. (2012) Human target validation of phosphoinositide 3-kinase (PI3K)β:
effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J. Thromb. Haemost. 10:
2127-36 [PMID:22906130]
86. Ohwada J, Ebiike H, Kawada H, Tsukazaki M, Nakamura M, Miyazaki T, Morikami K, Yoshinari K, Yoshida
M and Kondoh O et al.. (2011) Discovery and biological activity of a novel class I PI3K inhibitor,
CH5132799. Bioorg. Med. Chem. Lett. 21: 1767-72 [PMID:21316229]
87. Palanki MS, Dneprovskaia E, Doukas J, Fine RM, Hood J, Kang X, Lohse D, Martin M, Noronha G and
Soll RM et al.. (2007) Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective
inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. J.
Med. Chem. 50: 4279-94 [PMID:17685602]
88. Parkinson GN, Vines D, Driscoll PC and Djordjevic S. (2008) Crystal structures of PI3K-C2alpha PX
domain indicate conformational change associated with ligand binding. BMC Struct. Biol. 8: 13
6
[PMID:18312637]
89. Pemberton N, Mogemark M, Arlbrandt S, Bold P, Cox RJ, Gardelli C, Holden NS, Karabelas K, Karlsson J
and Lever S et al.. (2018) Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-
Kinase (PI3K)-γ Inhibitors. J. Med. Chem. 61: 5435-5441 [PMID:29852070]
90. Perry MWD, Björhall K, Bonn B, Carlsson J, Chen Y, Eriksson A, Fredlund L, Hao H, Holden NS and
Karabelas K et al.. (2017) Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-
Acting Inhaled Administration. J. Med. Chem. 60: 5057-5071 [PMID:28520415]
91. Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M
and Chabert C et al.. (2006) Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective
inhibitors of phosphoinositide 3-kinase gamma. J. Med. Chem. 49: 3857-71 [PMID:16789742]
92. Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L and Samson M et al.. (2012)
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and
phosphatidylinositol 3-kinase signaling. Clin. Cancer Res. 18: 4104-13 [PMID:22693356]
93. Rae W, Gao Y, Ward D, Mattocks CJ, Eren E and Williams AP. (2017) A novel germline gain-of-function
variant in PIK3CD. Clin. Immunol. 181: 29-31 [PMID:28578023]
94. Rageot D, Bohnacker T, Melone A, Langlois JB, Borsari C, Hillmann P, Sele AM, Beaufils F, Zvelebil M
and Hebeisen P et al.. (2018) Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-
azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly
Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. J. Med. Chem. 61:
10084-10105 [PMID:30359003]
95. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A
and Di Stefano F et al.. (2009) Biological properties of potent inhibitors of class I phosphatidylinositide 3-
kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther. 8: 1725-38
[PMID:19584227]
96. Ren P, Liu Y, Li L, Chan K, Wilson TE and Campbell SF.. (2013) Heterocyclic compounds and uses
thereof. Patent number: US20130035324 A1.
97. Ronan B, Flamand O, Vescovi L, Dureuil C, Durand L, Fassy F, Bachelot MF, Lamberton A, Mathieu M
and Bertrand T et al.. (2014) A highly potent and selective Vps34 inhibitor alters vesicle trafficking and
autophagy. Nat. Chem. Biol. 10: 1013-9 [PMID:25326666]
98. Sadhu C, Masinovsky B, Dick K, Sowell CG and Staunton DE. (2003) Essential role of phosphoinositide 3-
kinase delta in neutrophil directional movement. J. Immunol. 170: 2647-54 [PMID:12594293]
99. Shugg RP, Thomson A, Tanabe N, Kashishian A, Steiner BH, Puri KD, Pereverzev A, Lannutti BJ, Jirik FR
and Dixon SJ et al.. (2013) Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on
osteoclasts: actions on cytoskeletal organization, survival, and resorption. J. Biol. Chem. 288: 35346-57
[PMID:24133210]
100. Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, Folks A, Friedman L, Goldsmith R
and Gunzner J et al.. (2011) Discovery of a potent, selective, and orally available class I
phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980)
for the treatment of cancer. J. Med. Chem. 54: 7579-87 [PMID:21981714]
101. Taddei DMA, Onions ST, Smith AJ, Copmans AH and Broeckx RLM. (2016) Phosphoinositide 3-kinase
inhibitors Patent number: US9227977B2.
102. Tai AW, Bojjireddy N and Balla T. (2011) A homogeneous and nonisotopic assay for phosphatidylinositol
4-kinases. Anal. Biochem. 417: 97-102 [PMID:21704602]
103. Takeda AJ, Zhang Y, Dornan GL, Siempelkamp BD, Jenkins ML, Matthews HF, McElwee JJ, Bi W,
Seeborg FO and Su HC et al.. (2017) Novel PIK3CD mutations affecting N-terminal residues of p110δ
cause activated PI3Kδ syndrome (APDS) in humans. J. Allergy Clin. Immunol. 140: 1152-1156.e10
[PMID:28414062]
104. Tang P, Upton JEM, Barton-Forbes MA, Salvadori MI, Clynick MP, Price AK and Goobie SL. (2018)
Autosomal Recessive Agammaglobulinemia Due to a Homozygous Mutation in PIK3R1. J. Clin. Immunol.
38: 88-95 [PMID:29178053]
105. Taracido IC, Harrington EM, Honda A and Keaney E. (2014) Bi-heteroaryl compounds as Vps34 inhibitors
Patent number: US8685993.
106. Tsujita Y, Mitsui-Sekinaka K, Imai K, Yeh TW, Mitsuiki N, Asano T, Ohnishi H, Kato Z, Sekinaka Y and
Zaha K et al.. (2016) Phosphatase and tensin homolog (PTEN) mutation can cause activated
phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency. J. Allergy Clin. Immunol. 138: 1672-
1680.e10 [PMID:27426521]
107. Uddin M, Lau LC, Seumois G, Vijayanand P, Staples KJ, Bagmane D, Cornelius V, Dorinsky P, Davies DE
and Djukanović R. (2013) EGF-induced bronchial epithelial cells drive neutrophil chemotactic and anti-
apoptotic activity in asthma. PLoS ONE 8: e72502 [PMID:24039773]
108. Vakkalanka SKVS, Bhavar PK, Viswanadha S and Babu G. (2017) Dual selective PI3 delta and gamma
kinase inhibitors Patent number: US9790224B2.
109. Vakkalanka SKVS, Muthuppalaniappan M and Nagarathnam D.. (2014) Novel selective pi3k delta
inhibitors. Patent number: US20140011819 A1.
110. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, Higashi K, Volinia S,
7
Downward J and Waterfield MD. (1997) P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc.
Natl. Acad. Sci. U.S.A. 94: 4330-5 [PMID:9113989]
111. Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova
G, Brooijmans N, Mallon R and Hollander I et al.. (2010) Bis(morpholino-1,3,5-triazine) derivatives: potent
adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin
inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J. Med. Chem. 53: 2636-
45 [PMID:20166697]
112. Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, Blanc E, Johnson SC, Hoguin C and
Boccara O et al.. (2018) Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature
558: 540-546 [PMID:29899452]
113. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP and Williams RL. (2000)
Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin,
myricetin, and staurosporine. Mol. Cell 6: 909-19 [PMID:11090628]
114. Wentink M, Dalm V, Lankester AC, van Schouwenburg PA, Schölvinck L, Kalina T, Zachova R, Sediva A,
Lambeck A and Pico-Knijnenburg I et al.. (2017) Genetic defects in PI3Kδ affect B-cell differentiation and
maturation leading to hypogammaglobulineamia and recurrent infections. Clin. Immunol. 176: 77-86
[PMID:28104464]
115. Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J and Martin
CM et al.. (2013) PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses
activity in autoimmune and inflammatory disease models. Chem. Biol. 20: 1364-74 [PMID:24211136]
116. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC and
Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural
insights from biochemistry. Chem. Biol. 17: 1241-9 [PMID:21095574]
117. Wu P and Hu Y.. (2012) Small molecules targeting phosphoinositide 3-kinases. Medchemcomm 3: 1337-
1355
118. Xie C, He Y, Zhen M, Wang Y, Xu Y and Lou L. (2017) Puquitinib, a novel orally available PI3Kδ inhibitor,
exhibits potent antitumor efficacy against acute myeloid leukemia. Cancer Sci. 108: 1476-1484
[PMID:28418085]
119. Xu Z and Lou Y. (2017) Fused heterocyclic compound, preparation method therefor, pharmaceutcial
composition, and uses thereof Patent number: US20160244432A1.
120. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, Hirono S, Yamazaki K and Yamori T.
(2006) Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer Inst.
98: 545-56 [PMID:16622124]
121. Yang J, Shamji A, Matchacheep S and Schreiber SL. (2007) Identification of a small-molecule inhibitor of
class Ia PI3Ks with cell-based screening. Chem. Biol. 14: 371-7 [PMID:17462572]
122. Yu Y, Han Y, Zhang F, Gao Z, Zhu T, Dong S and Ma M. (2020) Design, Synthesis, and Biological
Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors. J. Med. Chem.
[PMID:32069401]
8
